semaglutide journal nejm Semaglutide, a glucagon-like peptide-1 (GLP-1) receptor agonist, has well-established weight-loss benefits. Cagrilintide, a long-acting analogue of the satiety hormone amylin, has shown promise for weight loss in early trials. The potential Semaglutide vs Tirzepatide in Weight

Effects of LX4211, a dual sodium-dependent glucose cotransporters 1 and 2 inhibitor, on postprandial glucose, insulin, glucagon-like peptide 1, and peptide tyrosine tyrosine in a dose-timing study in healthy subjects

Abdominal-Symptom Evaluation Severe or persistent abdominal symptoms should be evaluated medically rather than managed through routine self-testing

Apoptosis regulators

feel like i got my life back honestly James W., 41, Winnipeg MB Weeks 13-24 Summary: Peak Results Period Weight loss: 15-19 pounds this period (34-38 pounds total, ~17% of starting weight) Weekly loss rate: Averages 1.25-1.6 pounds weekly (slowing from early weeks but still excellent) Side effects: Minimal for most people

JAMA 300 , 509519 (2008)